Helicobacter pylori in Iran: A systematic review on the antibiotic resistance

Document Type : Review Article


1 Antimicrobial Resistance Research Center, Department of Medical Bacteriology and Virology, Qaem University Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

2 Department of Microbiology, School of Medicine¸ Isfahan University of Medical Sciences, Isfahan, Iran

3 Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

4 Department of Biostatistics and Epidemiology, School of Medicine¸ Isfahan University of Medical Sciences, Isfahan, Iran


Objective(s):Helicobacter pylori (H. pylori) is a pathogenic bacterium that colonizes the stomachs of approximately 50% of the world’s population. Resistance of H. pylori to antibiotics is considered as the main reason for the failure to eradicate this bacterium. The aim of this study was to determine the rate of resistant H. pylori strains to various antimicrobial agents in different areas of Iran.  
Materials and Methods: A systematic review of literatures on H. pylori antibiotic resistance in Iran was performed within the time span of 1997 to 2013. Data obtained from various studies were tabulated as following, 1) year of research and number strains tested, 2) number of H. pylori positive patients, 3) study place, 4) resistance of H. pylori to various antibiotics as percentage, and 5) methods used for evaluation of antibiotic resistance.
Results: Over the period, a total of 21 studies on H. pylori antibiotic resistance have been conducted in different parts of Iran. In these studies, H. pylori resistance to various antibiotics, including metronidazole, clarithromycin, amoxicillin, tetracycline, ciprofloxacin, levofloxacin and furazolidone were 61.6%, 22.4% ,16.0%, 12.2%, 21.0%, 5.3% and 21.6%, respectively. We found no study on                 H. pylori resistance to rifabutin in Iran.
Conclusion: Compared to the global average, we noted that the prevalence of H. pylori resistance to metronidazole, clarithromycin, amoxicillin, and tetracycline has been rapidly growing in Iran. This study showed that in order to determine an appropriate drug regimen against H. pylori, information on antibiotic susceptibility of the bacterium within different geographical areas of Iran is required.


1. Hosseini E, Poursina F, Van de Wiele T, Safaei HG, Adibi P. Helicobacter pylori in Iran: A systematic review on the association of genotypes and gastroduodenal diseases. J Res Med Sci 2012; 17:280-292.
2. Tanih NF, Clarke AM, Mkwetshana N, Green E, Ndip LM, Ndip RN. Helicobacter pylori infection in Africa: Pathology and microbiological diagnosis. Afr J Biotechnol 2008; 7:4653-4662.
3. Jones KR, Cha J-H, Merrell DS. Who’s winning the war? Molecular mechanisms of antibiotic resistance in Helicobacter pylori. Curr Drug ther 2008; 3:190-203.
4. Rimbara E, Noguchi N, Kijima H, Yamaguchi T, Kawai T, Sasatsu M. Mutations in the 23S rRNA gene of clarithromycin-resistant Helicobacter pylori from Japan. Int J Antimicrob Agents 2007; 30: 250-4.
5. Beswick EJ, Suarez G, Reyes VE. Helicobacter pylori and host interactions that influence pathogenesis. World J Gastroenterol 2006; 12:5599-5605.
6. Gerrits MM, van Vliet AH, Kuipers EJ, Kusters JG. Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications. Lancet Infect Dis 2006; 6:699-709.
7. Khademi F, Faghri J, Poursina F, Esfahani BN, Moghim S, Fazeli H, et al. Resistance pattern of Helicobacter pylori strains to clarithromycin, metronidazole and amoxicillin in Isfahan, Iran. J Res Med Sci 2013; 18:1056-1560.
8. Baglan PH, Bozdayi G, Ozkan M, Ahmed K, Bozdayi AM, Ozden A. Clarithromycin resistance prevalence and Icea gene status in Helicobacter pylori clinical isolates in Turkish patients with duodenal ulcer and functional dyspepsia. JMicrobiol 2006; 44:409-416.
9. Yu JD, Chen J, Li ZY, Zhang XP. Prevalence of Helicobacter pylori resistant to clarithromycin, metronidazole and amoxicillin isolated from pediatric patients in China. World J Pediatr 2006; 1: 49-52.
10. De Francesco V, Giorgio F, Hassan C, Manes G, Vannella L, Panella C, et al. Worldwide Helicobacter pylori Antibiotic Resistance: a Systematic. J Gastrointestin Liver Dis 2010; 19:409-414.
11. Siavoshi F, Saniee P, Latifi-Navid S, Massarrat S, Sheykholeslami A. Increase in resistance rates of Helicobacter pylori isolates to metronidazole and tetracycline-comparison of three 3-year studies. Arch Iran Med 2010; 13: 177-187.
12. Siavashi F, Safari F, Doratotaj D, Khatami GR, Falahi GH, Mirnaseri S. Antimicrobial resistance of Helicobacter pylori isolates from Iranian adults and children. Arch Iran Med 2006; 9:308-314.
13. Rafeey M, Ghotaslou R, Nikvash S, Ashrafy Hafez A. Primary resistance in Helicobacter pylori isolated in children from Iran. J Infect Chemother 2007; 13:291-295.
14. Sirous M, Mehrabadi JF, Daryani N, Eshraghi S, Hajikhani S, Shirazi M. Prevalence of antimicrobial resistance in Helicobacter pylori isolates from Iran. Afr J Biotechnol 2010; 9:5962-5965.
15. Fallahi GH, Maleknejad S. Helicobacter pylori culture and antimicrobial resistance in Iran. Indian J Pediatr 2007; 74:127-130.
16. Abdollahi H, Savari M, Zahedi MJ, Moghadam SD, Hayatbakhsh Abasi M. Detection of A2142C, A2142G, and A2143G Mutations in 23s rRNA Gene Conferring Resistance to Clarithromycin among Helicobacter pylori isolates in Kerman, Iran. Iran J Med Sci 2011; 36:104-110.
17. Megraud F. Helicobacter pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004; 53:1374-1384.
18. Hunt R, Xiao S, Megraud F, Leon-Barua R, Bazzoli F, van der Merwe S, et al. Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline. J Gastrointestin Liver Dis 2011; 20:299-304.
19. Khashei R, Shojaei H, Adibi P, Shavakhi A, Aslani MM, Daei Naser A. Genetic diversity and drug resistance of Helicobacter pylori strains in Isfahan, Iran. Iran J Basic Med Sci 2008; 11:174-182.
20.    Tomatari FH, Mobarez AM, Amini M, Hosseini D, Abadi ATB. Helicobacter pylori resistance to metronidazole and clarithromycin in dyspeptic patients in Iran. Iran Red Crescent Med J 2010; 12:409-412.
21. Falsafi T, Mobasheri F, Nariman F, Najafi M. Susceptibilities to different antibiotics of Helicobacter pylori strains isolated from patients at the pediatric medical center of Tehran, Iran. J Clin Microbiol 2004; 42: 387-389.
22. Mohammadi M, Doroud D, Mohajerani N, Massarrat S. Helicobacter pylori antibiotic resistance in Iran. World J Gastroenterol 2005; 11: 6009-6013.
23. Kohanteb J, Bazargani A, Saberi-Firoozi M, Mobasser A. Antimicrobial susceptibility testing of Helicobacter pylori to selected agents by agar dilution method in Shiraz-Iran. Indian J Med Microbiol 2007; 25:374-377.
24. Talebi Bezmin Abadi A, Mobarez AM, Taghvaei T, Wolfram L. Antibiotic resistance of Helicobacter pylori in Mazandaran, North of Iran. Helicobacter 2010; 15:505-509.
25. Abadi ATB, Taghvaei T, Mobarez AM, Carpenter BM, Merrell DS. Frequency of antibiotic resistance in Helicobacter pylori strains isolated from the northern population of Iran. J  Microbiol 2011; 49:987-993.
26. Farshad S,  Alborzi A, Japoni A, Ranjbar R, Hosseini Asl K, Badiee Pet al. Antimicrobial susceptibility of Helicobacter pylori strains isolated from patients in Shiraz, Southern Iran. World J Gastroenterol 2010; 16: 5746-5751.
27. Talebi Bezmin Abadi A, Ghasemzadeh A, Taghvaei T, Mobarez AM. Primary resistance of Helicobacter pylori to levofloxacin and moxifloxacine in Iran. Intern Emerg Med 2012; 7:447-452. 4
28. Shokrzadeh L, Jafari F, Dabiri H, Baghaei K, Zojaji H, Alizadeh AH, et al. Antibiotic susceptibility profile of Helicobacter pylori isolated from the dyspepsia patients in Tehran, Iran. Saudi J Gastroenterol 2011; 17:261-264.
29. Kargar M, Baghernejad M, Doosti A, Ghorbani-Dalini S. Clarithromycin resistance and 23S rRNA mutations in Helicobacter pylori isolates in Iran. Afr J Microbiol Res 2011; 5:853-856.
30. Mirzaei N, Poursina F, Faghri J,  Talebi M,  Khataminezhad MR, Hasanzadeh A, et al. Prevalence of resistance to Helicobacter pylori strains to selected antibiotics in Isfahan, Iran. J Microbiol 2013; 6:e6342.
31. Saberi-Firoozi M, Nejabat M. Experiences with Helicobacter pylori treatment in Iran. Iran J Med Sci 2006; 31:181-185.
32. Khatibian M, Ajvadi Y, Nasseri-Moghaddam S, Ebrahimi-Dariani N, Vahedi H, Zendehdel Net al. Furazolidone-based, metronidazole-based, or a combination regimen for eradication of Helicobacter pylori in peptic ulcer disease. Arch Iran Med 2007; 10: 161-167.
33. Malekzadeh R, Ansari R, Vahedi H,  Siavoshi F, Alizadeh BZ, Eshraghian MRet al. Furazolidone versus metronidazole in quadruple therapy for eradication of Helicobacter pylori in duodenal ulcer disease. Aliment PharmacolTher 2000; 14:299-303.